Cargando…

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers

Poly (ADP-ribose) polymerases (PARPs) play an important role in various cellular processes, such as replication, recombination, chromatin remodeling, and DNA repair. Emphasizing PARP’s role in facilitating DNA repair, the PARP pathway has been a target for cancer researchers in developing compounds...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keung, Man Yee T., Wu, Yanyuan, Vadgama, Jaydutt V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517993/ https://www.ncbi.nlm.nih.gov/pubmed/30934991 http://dx.doi.org/10.3390/jcm8040435

Ejemplares similares

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer
por: Dutta, Pranabananda, et al.
Publicado: (2020)

Genetic variants in African-American and Hispanic patients with breast cancer
por: Dutta, Pranabananda, et al.
Publicado: (2022)

Epithelial-Mesenchymal Transition and Breast Cancer
por: Wu, Yanyuan, et al.
Publicado: (2016)

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
por: Póti, Ádám, et al.
Publicado: (2019)

GROα overexpression drives cell migration and invasion in triple negative breast cancer cells
por: Bhat, Kruttika, et al.
Publicado: (2017)

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits
por: CHUNG, SEYUNG S., et al.
Publicado: (2013)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN
por: Wu, Yanyuan, et al.
Publicado: (2013)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women
por: Wu, Yanyuan, et al.
Publicado: (2017)

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
por: Wu, Yanyuan, et al.
Publicado: (2010)

Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies
por: Hao, Qiongyu, et al.
Publicado: (2022)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
por: Xie, Tao, et al.
Publicado: (2022)

Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women
por: Wu, Yanyuan, et al.
Publicado: (2022)

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment
por: Austin, David, et al.
Publicado: (2018)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
por: Verma, Priyanka, et al.
Publicado: (2021)

IGF-1 Regulates Cyr61 Induced Breast Cancer Cell Proliferation and Invasion
por: Sarkissyan, Suren, et al.
Publicado: (2014)

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
por: Gu, Yayun, et al.
Publicado: (2021)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
por: De Lorenzo, Silvana B., et al.
Publicado: (2013)

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer
por: Hamilton, Nalo, et al.
Publicado: (2017)

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
por: Schoonen, Pepijn M., et al.
Publicado: (2017)

Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
por: Wu, Yanyuan, et al.
Publicado: (2008)

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines
por: Wikiniyadhanee, Rakkreat, et al.
Publicado: (2023)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

Tumor-Derived Exosomes in Tumor-Induced Immune Suppression
por: Hao, Qiongyu, et al.
Publicado: (2022)

The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
por: Elshimali, Yahya I., et al.
Publicado: (2013)

Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets
por: Nava, Miguel, et al.
Publicado: (2019)

Roles of Protein Disulfide Isomerase in Breast Cancer
por: Yang, Suhui, et al.
Publicado: (2022)

Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice
por: Wu, Yanyuan, et al.
Publicado: (2014)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022)

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
por: Mekonnen, Negesse, et al.
Publicado: (2022)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors
por: Wang, Junhui, et al.
Publicado: (2015)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance
por: Nava, Miguel, et al.
Publicado: (2019)

hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors
por: Gundogdu, Ramazan, et al.
Publicado: (2021)

AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
por: Cao, Wei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_617io2lokttpro3ndm24h0vfab